Leukemia

Young adults who received radioactive iodine therapy for differentiated thyroid cancer were at 92% increased risk for leukemia and 23% increased risk for any solid malignancies vs. those who did not receive radioactive iodine therapy.

A collaborative team of cancer experts from leading academic institutions and organizations has released recommendations for optimal protection against COVID-19 among individuals with blood cancer.

Cierra Aber is a helper.

American Association for Cancer Research urged the CDC to expand availability of COVID-19 booster vaccinations to caregivers and other individuals who share a home with patients with cancer.

The FDA granted orphan drug designation to LAVA-051 for the treatment of chronic lymphocytic leukemia.

Patients with lymphoid malignancies who received anti-CD20 therapy within the previous year did not demonstrate antibody responses to the messenger RNA COVID-19 vaccines, according to study results published in Blood Advances.

In this video, Farhad Ravandi, MD, spoke with Healio about the importance of measurable residual disease assessment in AML, which was discussed at the Society of Hematologic Oncology Annual Meeting.

ASH will honor Donna S. Neuberg, ScD, with the 2021 Exemplary Service Award at this year’s ASH Annual Meeting, scheduled for Dec. 11-14.

Demographic reporting requirements established more than a decade ago to improve diversity in acute leukemia clinical trials did not appear to result in greater enrollment of Black and Hispanic patients, according to a study in Blood Advances.

The FDA approved brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.